Last reviewed · How we verify

Aleor Dermaceuticals Limited — Portfolio Competitive Intelligence Brief

Aleor Dermaceuticals Limited pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Differin 0.3% Topical Gel Differin 0.3% Topical Gel phase 3 Retinoid (third-generation) Retinoic acid receptor gamma (RARγ) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Apotex Inc. · 1 shared drug class
  2. Galderma R&D · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aleor Dermaceuticals Limited:

Cite this brief

Drug Landscape (2026). Aleor Dermaceuticals Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aleor-dermaceuticals-limited. Accessed 2026-05-16.

Related